Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
The PLANET Study aims to determine the impact of microplastics on intestinal inflammation and
gut microbiome in order to understand the role of this pollutant on the risk of developing
inflammatory bowel disease (IBD) as well as other diseases. With this information...
Age: 18 years - 66+
Gender: All
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to
receive mirikizumab or another intervention. The purpose of the mirikizumab study is to
evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of
...
Age: 2 - 17 years
Gender: All
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
The purpose of this study is to evaluate the efficacy, safety, drug levels, and drug effects
of ozanimod in pediatric participants with moderately to severely active Crohn's Disease.
Age: 2 - 17 years
Gender: All
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing,
perianal Crohn's disease and to assess the overall safety of guselkumab.
Age: 18 years - 66+
Gender: All
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC)
ustekinumab
Age: 2 - 17 years
Gender: All
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in
pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will
last about 172 weeks and may include up to 44 visits.
Age: 2 - 19 years
Gender: All
Proactive Infliximab Optimization Using a PK Dashboard Versus SOC in Patients With Crohn's Disease: The OPTIMIZE Trial
The OPTIMIZE Trial compares whether iDose dashboard-driven infliximab dosing (iDose-driven
dosing) is more effective and safer than standard infliximab dosing for inducing and
maintaining disease remission in moderately to severely active CD.
Age: 16 years - 66+
Gender: All
Low Dose IL-2 for the Treatment of Crohn's Disease
The purpose of this study is to determine the safety and maximum effective dose (MED) of
Interleukin-2 in subjects with moderate-to-severe crohn's disease.
Age: 18 - 80 years
Gender: All
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
Crohn's disease (CD) is the major form of inflammatory bowel disease (IBD) affecting adults.
It is a life-long disease characterized by chronic and relapsing inflammation of the
gastrointestinal tract. CD has multiple clinical phenotypes and disease severities that
...
Age: 18 - 30 years
Gender: All
Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease
The MELODY Trial: Modulating Early Life Microbiome through Dietary Intervention in Crohn's
Disease, will test whether a non-invasive dietary intervention during pregnancy can improve
the gut microbiota composition in both pregnant Crohn's disease patients and their ...
Age: 18 years - 66+
Gender: Female
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
This study will evaluate the safety of oral administration of EcoActive to patients with
inactive Crohn's disease and how it affects the levels of AIEC in stool.
Age: 18 years - 66+
Gender: All
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
The purpose of this study is to compare the efficacy of treatment with ustekinumab or
adalimumab in biologic naive participants with moderately-to-severely active Crohn's disease
(CD) who have previously failed or were intolerant to conventional therapy (corticosteroi...
Age: 18 years - 66+
Gender: All
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients
(age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical
practice. TARGET-IBD will create a research registry of patients with IBD within academic...
Age: 2 years - 66+
Gender: All
Autologous Stem Cell Transplant for Crohn's Disease
Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant
complications and discomfort in the stomach and intestines. Crohn's disease is a
debilitating, incurable disease of immune cells; it affects almost 1 million people in the
United Sta...
Age: 18 years - 66+
Gender: All
A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the pharmacokinetics (PK) of ustekinumab in subjects
from 2 through less than (<) 18 years old in the USA, or 6 through less than (<) 18 years old
in other countries and determine if it is similar to that observed in adults wit...
Age: 2 - 17 years
Gender: All